Smaller Biopharma companies are emerging as the leading stakeholders in the clinical development of new therapies. In fact, small and emerging biopharma companies are projected to conduct 50 percent of the clinical trials in the US in 2025. These companies are frequently faced with complex challenges related to the design, launch, and operations associated with new clinical development programs. This stream includes two unique tracks, each featuring its own set of topics and speakers.